Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name CD274 amp
Gene Variant Detail

CD274 amp (no effect)

Relevant Treatment Approaches PD-L1/PD-1 antibody

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 amp carcinoma sensitive PD-L1/PD-1 antibody Pembrolizumab Case Reports/Case Series Actionable In a clinical case study, a patient with cancer of unknown primary harboring CD274 amplification and overexpression, and a hypermutated genome was sensitive to Keytruda (pembrolizumab), demonstrating tumor regression after two months of treatment and a near complete remission after six months of treatment (PMID: 27900363). 27900363
CD274 amp basal cell carcinoma predicted - sensitive PD-L1/PD-1 antibody Nivolumab Case Reports/Case Series Actionable In a clinical case study, a patient with metastatic basal cell carcinoma harboring CD274 amplification and a high mutational burden was sensitive to treatment with Opdivo (nivolumab), demonstrating reduced lesion size after two months of treatment and a nearly complete regression of liver lesions after four months of treatment (PMID: 27942391). 27942391
CD274 amp Advanced Solid Tumor predicted - sensitive PD-L1/PD-1 antibody unspecified PD-1 antibody Case Reports/Case Series Actionable In a clinical study, 66.7% (6/9) of advanced solid tumor patients harboring CD274 amplification demonstrated an objective response when treated with a PD-1/PD-L1 monotherapy (5 patients), a PD-1/PD-L1 therapy combined with an investigational drug (3 patients), or a combination of an anti-PD-1 and anti-CTLA4 therapy (1 patient) (PMID: 29902298). 29902298
CD274 amp Advanced Solid Tumor predicted - sensitive PD-L1/PD-1 antibody unspecified PD-L1 antibody Clinical Study Actionable In a clinical study, 66.7% (6/9) of advanced solid tumor patients harboring CD274 amplification demonstrated an objective response when treated with a PD-1/PD-L1 monotherapy (5 patients), a PD-1/PD-L1 therapy combined with an investigational drug (3 patients), or a combination of an anti-PD-1 and anti-CTLA4 therapy (1 patient) (PMID: 29902298). 29902298
CD274 amp lung non-small cell carcinoma predicted - sensitive PD-L1/PD-1 antibody Nivolumab Clinical Study - Cohort Actionable In a clinical study, treatment with Opdivo (nivolumab) did not result in a significant overall response rate (ORR) in non-small cell lung cancer (NSCLC) patients with a CD274 copy number gain (CNG; amplification and polysomy) vs patients without a CNG (28.1% vs. 17.9%; p=0.22), but NSCLC patients with CD274 amplification demonstrated an ORR of 80% (4/5), a 1-year progression-free survival of 80%, a 1-year overall survival of 100%, and the median duration of response was not yet reached (PMID: 32955570). 32955570
CD274 amp lung non-small cell carcinoma predicted - sensitive PD-L1/PD-1 antibody Nivolumab Case Reports/Case Series Actionable In a clinical case study, a CD274 (PD-L1) amplified non-small cell lung carcinoma patient treated with Opdivo (nivolumab) achieved stable disease with a 20% reduction in tumor growth and a progression-free survival of 9.7 months (PMID: 32955570). 32955570